

Haematologica
HAEMATOL/2018/208603
Version 2

Sequential and combination treatments with novel agents in chronic
lymphocytic leukemia

Moritz Fürstenau, Michael Hallek, and Barbara Eichhorst

Disclosures: Moritz Fürstenau declares no conflict of interest. Michael Hallek: Research support for Roche, Gilead, Mundipharma, Janssen, Celgene, Pharmacyclics, Abbvie. Speakers bureau and Advisory Board: Roche Gilead, Mundipharma, Janssen, Celgene, Pharmacyclics, Boehringer Barbara Eichhorst: Research grants from Abbvie, Gilead, Janssen, Roche. Honoraria and advisory boards from the same companies and Celgene and Novartis in addition.

Contributions: All authors participated equally in writing and reviewing the manuscript.